Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Repotrectinib in ROS1-positive NSCLC with Active Brain Metastasis
NCT06315010Phase 2Recruiting
- Sponsor
- MEDSIR
- Start
- Jun 2025
- Primary completion
- Mar 2027
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 3
01
Overview
A Phase 2 trial of repotrectinib in non-small cell lung cancer (NSCLC), sponsored by MEDSIR. Started Jun 2025; status: recruiting.
02
Drugs
repotrectinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06315010.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06315010.